Background and Aims: Lung cancer is the leading cause of mortality in all patients with cancer. The standard first line treatment of lung adenocarcinoma harbouring sensitive epidermal growth factor receptor (EGFR) mutation is EGFR-tyrosine kinase inhibitors (TKIs). Several studies compared treatment response rate, survival, and side effect among different EGFR-TKIs and the results showed gefitinib was the least effective one among EGFR-TKIs. However, in our practice, the response rate between gefitinib and erlotinib was similar. Thus, we conduct this study for clarified this issue.
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Methods: This is a retrospective cohort study of non-small lung cancer (NSCLC) patients harbouring sensitive EGFR mutation receiving 1st line EGFR-TKIs in National Taiwan University Hospital Hsinchu branch from January 1, 2010 to Dec 31, 2015. Clinical response and survival after receiving first line erlotinib or gefitinib were compared using logistic and Cox regression analyses, respectively.
Results: There were 175 patients enrolled, including 140 (80%) patients received gefitinib, and 35 (20%) patients received erlotinib. Erlotinib group were more likely to be non-adenocarcinoma cell type, and chronic kidney disease. In survival analysis, patients receiving erlotinib or gefitinib were associated with similar progression free survival (PFS) (9.5 vs 9.7 months; HR, 1.14; 95% CI, 0.75 to 1.75) and overall survival (OS) (16.8 vs 18.9 months; HR, 1.26; 95% CI, 0.78 to 2.04). However, in patient with L858R mutation, lower PFS in erlotinib compared with gefitinib (9.2 vs 6.0 months; HR, 2.43; 95% CI, 1.27 to 4.66), and OS (17.7 vs 13.2 months; HR, 3.75; 95% CI, 1.84 to 7.66) were found.
Conclusion:
In NSCLC patients harbouring sensitive EGFR mutation, first line erlotinib and gefitinib showed similar clinical response. However, in L858R subgroup, gefitinib seems more effective than erlotinib. Further large scale randomized controlled trials are necessary for confirming the result. Abstracts abdominal CT showed gastric wall thickening and multiple small lymph nodes enlargement around the stomach. Lung tumor was diagnosed as adenocarcinoma, cT4N2M1a (PLE), EGFR negative, ALK negative, PD-L1 (TPS) 90%. Gastrointestinal endoscopy revealed advanced gastric cancer with multiple ulcers, which TPS was negative. Surgical treatment was not selected for gastric cancer because of high risk of anaesthesia, chemotherapy for both of lung cancer and gastric cancer was preceded. Pembrolizumab was administered as the first line therapy in April 2017. After administration, the lung tumor was reduced, and the lesions of gastric cancer are also stable without exacerbation or bleeding. The patient has continued pembrolizumab for 1 year and 2 months without disease progression.
Results: In present case, pembrolizumab are effective to both of lung cancer and gastric cancer. It is believed that environmental factors such as smoking are cause of multiple cancers and related to high numbers of mutation of tumor genome. As smoking is one of the prognosis factor of anti-PD-1 therapy, the present case might demonstrate an effectiveness of pembrolizumab even for gastric cancer though its TPS is negative.
Conclusion: ICI such as pembrolizumab might be effective in synchronous multiple cancers, especially in smoking patients. Methods: Patients with EGFR mutation-positive advanced NSCLC who visited a tertiary referral center from December 1, 2013, to November 30, 2017, were analyzed retrospectively. They received gefitinib, erlotinib, or afatinib until disease progression, death, or intolerable adverse events.
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The cumulative incidence of subsequent BM of initial non-BM patients, progression-free survival (PFS), and overall survival (OS) of the BM and non-BM patients were estimated and compared using the Kaplan-Meier and log-rank tests.
Results: 306 NSCLC patients were enrolled, with 116, 75, and 115 receiving first-line gefitinib, erlotinib, and afatinib, respectively. The afatinib group had a better PFS (12.7 vs 9.8 months; HR 0.59, P = 0.001) and OS (39.1 vs 22.0 months; HR 0.64, P = 0.035) than the gefitinib group. Afatinib tended to provide better BM prevention than gefitinib (BM cumulative incidence, HR 0.49; 95% CI: 0.34-0.71, P < 0.001) according to a Cox model adjusted for possible confounders. Patients with initial BM had a shorter PFS (P < 0.001) and OS (P = 0.015) than those without initial BM. Among the former, there were no differences in median PFS (P = 0.34) and median OS (P = 0.46) in the three EGFR-TKI groups.
Conclusion: Our data suggested that, compared to gefitnib, afatinib provided significant benefits in terms of PFS and OS in treating BM. Both had the same effectiveness in preventing subsequent BM. Background and Aims: Primary Pulmonary Synovial Sarcoma is a highly aggressive and extremely rare tumor. A 31-year-old female, Overseas Filipino Worker, underwent routine chest radiograph wherein a left sided pleural effusion was found incidentally. The patient denied any respiratory symptoms. She had pleural biopsy and was advised for further work up however she decided to go back to the Philippines. Few days prior to admission, she had difficulty of breathing prompted consult to our institution and was subsequently admitted. The Patient arrived in the emergency room in cardiopulmonary distress. She was pale and chest examination revealed asymmetrical chest expansion, no retractions, absent tactile and vocal fremitus and absent breath sounds on the left lung field.
Methods: To report a case of 31 years old asymptomatic female with primary Pulmonary Synovial Sarcoma.
Results: A massive pleural effusion with contralateral mediastinal shifting was seen on Chest radiograph. On Contrast Enhanced Computed Tomography of thorax showed multiple heterogeneous lesion of the pleural fluid contained within the thickened contrast-enhanced rim septations occupying almost the entire left hemithorax. Patient underwent videoassisted thoracoscopic surgery with frozen section biopsy and chest tube thoracostomy. Pleural fluid analysis revealed predominance of segmenters (60%), exudative with haemorrhagic pleural fluid. Furthermore, the pleural fluid was negative for acid fast bacilli and no growth on culture.
